Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer
- 1 June 2004
- journal article
- review article
- Published by Elsevier BV in Seminars in Oncology
- Vol. 31, 23-30
- https://doi.org/10.1053/j.seminoncol.2004.04.010
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- The Cancer Patient and Quality of LifeThe Oncologist, 2002
- What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire?: Results from Eastern Cooperative Oncology Group (ECOG) Study 5592Journal of Clinical Epidemiology, 2002
- Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (IressaTM), a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR)Lung Cancer, 2000
- Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer TherapyDrugs, 2000
- Management Issues for Stage IV Non-Small-Cell Lung CancerCancer Control, 1997
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995
- Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrumentLung Cancer, 1995